The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction

Ali A Rizvi,1 Manfredi Rizzo2 1Department of Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA; 2Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, ItalyCorrespondence: Ali A Riz...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Diabetes, Metabolic Syndrome and Obesity
المؤلفون الرئيسيون:	Rizvi AA, Rizzo M
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Dove Medical Press 2022-04-01
الموضوعات:	type 2 diabetes incretins glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide
الوصول للمادة أونلاين:	https://www.dovepress.com/the-emerging-role-of-dual-glp-1-and-gip-receptor-agonists-in-glycemic--peer-reviewed-fulltext-article-DMSO

مواد مشابهة

Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract
حسب: Nadya M. Morrow, وآخرون
منشور في: (2021-09-01)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
حسب: W. Timothy Garvey, وآخرون
منشور في: (2024-06-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
حسب: Jonathan D. Douros, وآخرون
منشور في: (2025-02-01)

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects
حسب: Akihiro Hamasaki, وآخرون
منشور في: (2024-06-01)

Physiology and clinical applications of GIP
حسب: Shunsuke Yamane, وآخرون
منشور في: (2025-07-01)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
حسب: Bartłomiej Stachyra, وآخرون
منشور في: (2023-04-01)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
حسب: Alessia Costa, وآخرون
منشور في: (2022-01-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
حسب: Aleksandra Grzegorczyk, وآخرون
منشور في: (2025-01-01)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
حسب: Katherine O. Kopp, وآخرون
منشور في: (2024-07-01)

The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis
حسب: Bashaier Al-Zaid, وآخرون
منشور في: (2025-03-01)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
حسب: Martin Haljeta Friedrichsen, وآخرون
منشور في: (2023-12-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
حسب: Claire H. Feetham, وآخرون
منشور في: (2025-09-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
حسب: E A Shestakova, وآخرون
منشور في: (2014-10-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
حسب: Ekaterina Alekseevna Shestakova
منشور في: (2011-09-01)

Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women
حسب: Sonya Vasto, وآخرون
منشور في: (2022-02-01)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
حسب: Zhuqing Meng, وآخرون
منشور في: (2023-03-01)

Tirzepatide – a new analogue of incretin hormones
حسب: Gabriela Anglart, وآخرون
منشور في: (2023-10-01)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation
حسب: Wathik Alsalim, وآخرون
منشور في: (2023-03-01)

Effects of passage through the digestive tract on incretin secretion: Before and after birth
حسب: Seiichi Tomotaki, وآخرون
منشور في: (2021-06-01)

Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”
حسب: Tian-Yi Ren, وآخرون
منشور في: (2024-10-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
حسب: Alexandros Leonidas Liarakos, وآخرون
منشور في: (2023-07-01)

The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
حسب: Muhammad Umar Mahar, وآخرون
منشور في: (2024-12-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
حسب: Szymon Jonik, وآخرون
منشور في: (2022-02-01)

Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
حسب: Chang Ho Ahn, وآخرون
منشور في: (2023-02-01)

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
حسب: Jang Won Son, وآخرون
منشور في: (2024-04-01)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
حسب: Giovanni Pacini, وآخرون
منشور في: (2022-05-01)

Ingestion of coffee polyphenols increases postprandial release of the active glucagon-like peptide-1 (GLP-1(7–36)) amide in C57BL/6J mice
حسب: Yoshie Fujii, وآخرون
منشور في: (2015-01-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
حسب: Alexander C. Martins, وآخرون
منشور في: (2024-04-01)

TGR5, GLP-1, and GIP expression in diabetic Wistar rats in response to Ficus exasperata vahl leaf extract
حسب: Olorunsola Israel Adeyomoye, وآخرون
منشور في: (2024-08-01)

Variation in responses to incretin therapy: Modifiable and non-modifiable factors
حسب: Gregory O. Austin, وآخرون
منشور في: (2023-04-01)

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
حسب: Shu-Chen Lu, وآخرون
منشور في: (2021-05-01)

Gut Hormones and Inflammatory Bowel Disease
حسب: Jonathan Weng, وآخرون
منشور في: (2025-07-01)

Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes
حسب: Saeed Reza Eshghi, وآخرون
منشور في: (2017-07-01)

The evolution of the therapeutic concept ‘GIP receptor antagonism’
حسب: Frederikke Koefoed-Hansen, وآخرون
منشور في: (2025-05-01)

Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide
حسب: Yuki Oe, وآخرون
منشور في: (2025-05-01)

Insulin and incretin responses to grazing in insulin‐dysregulated and healthy ponies
حسب: Danielle M. Fitzgerald, وآخرون
منشور في: (2019-01-01)

Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
حسب: Gemma Pujadas, وآخرون
منشور في: (2022-11-01)

Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide
حسب: Mark L. Hartman, وآخرون
منشور في: (2025-08-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
حسب: Alexander Sergeevich Ametov
منشور في: (2015-12-01)

Genetic variability of incretin receptors affects the occurrence of neurodegenerative diseases and their characteristics
حسب: David Vogrinc, وآخرون
منشور في: (2024-10-01)